On Jan. 9, the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:

The FDA is proposing to end the use of four chemical solvents under its color additive regulations, it said in a pair of notices released Jan. 10. In one notice, the agency said that it filed a petition to remove provisions from the regulations for ethylene dichloride, methylene chloride and trichloroethylene. In the other, the FDA said it filed a petition to remove benzene, as well as other uses of ethylene dichloride, methylene chloride and trichloroethylene. The petitions say the chemicals have been found to cause cancer. Comments are due March 11.

The FDA on Jan. 8 announced the availability of new ways to submit cosmetic facility registrations and cosmetic product listings that will be required from foreign and domestic facilities beginning in July 2024. One is a new electronic submission method using a structured product labeling tool, as mandated by the Modernization of Cosmetics Regulation Act of 2022, which created the cosmetics registration requirements. FDA Forms 5066 and 5067 are also now available as a tool to provide cosmetic product facility registration and product listing information to the FDA. “While electronic submission is not required, FDA strongly encourages electronic submissions to facilitate efficiency and timeliness of data submission and management for the agency,” the FDA said. The original deadline for submission of cosmetics facilities was the end of 2023, but FDA extended it in November (see 2311080085).

On Jan. 8, the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:

On Jan. 5, the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:

The FDA announced its approval of the state of Florida for the agency’s drug importation program, which allows imports of prescription drugs from Canada if they reduce costs for U.S. consumers without imposing additional risks to the public (see 2009290018), the FDA said in a news release Jan. 5. Under the program, Florida still must submit more drug-specific information for FDA approval, test the drugs it seeks to import and relabel the drugs to be consistent with FDA requirements. The program was approved for two years from the date of the first importation, the FDA said.

On Jan. 4, the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:

On Jan. 3, the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:

On Jan. 2, the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:

On Dec. 28, the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of: